Amicus Therapeutics (FOLD) Tops Q3 EPS by 8c, Revenues Miss; Raises FY19 Galafold Revenue Guidance
Tweet Send to a Friend
Amicus Therapeutics (NASDAQ: FOLD) reported Q3 EPS of ($0.24), $0.08 better than the analyst estimate of ($0.32). Revenue for the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
